MISSION AND PURPOSE
Omeza® is a leading evidence-based medical technology and consumer healthcare products company based in Sarasota, FL USA. Initially focused on closing chronic wounds and preventing their recurrence, the Omeza mission is to improve healthcare efficiency one market at a time, beginning with wound care.
Omeza end-users are people who have or are at risk for developing chronic wounds due to aging — exacerbated by comorbidities including diabetes, obesity, chronic venous insufficiency, peripheral artery disease and autoimmune disease. Current standard care of saline and gauze is ineffective, with wound closure hindered by biofilm, excessive debridement, and inadequate provider training that results in stalled wounds and expensive, often ineffective advanced wound care treatments. These wounds frequently result in costly hospital admissions and amputations.
Our performance-based bundle of Omeza products to treat venous leg ulcers, diabetic foot ulcers, pressure ulcers and surgical wounds. Initial product line includes: Omeza Lidocaine Lavage and Omeza Skin Protectant.
Omeza was founded by Thomas Gardner, a seasoned global pharmaceutical and skin care executive, and Griscom (Chip) Bettle, a renowned chemical engineer and inventor. In partnership with Dr. Desmond Bell, DPM, CWS, a leader in limb salvage and lower extremity wound care, the core ingredient formulation of the Omeza product line was created to support a dramatic increase in the healing rate of Venous Leg Ulcers (VLUs) and Diabetic Foot Ulcers (DFUs).
Since the company’s formation in 2017, the first products in the initial lineup, based upon a proprietary omega oil formulation, are being launched and used in a variety of settings. From controlled consumer testing to use in physician supervised settings, the products are generating positive case studies. Formalized testing to achieve more statistically significant results will commence in Q3 2019.